Horizon Pharma plc Announces FDA Approval to Expand the Age Range for Ravicti (glycerol phenylbutyrate) Oral Liquid to Include Newborns

DUBLIN--(BUSINESS WIRE)--Dec. 27, 2018-- Horizon Pharma plc (NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to expand the age range for Ravicti (glycerol...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news